Non-Small Cell Lung Cancer

Heterogeneity of Drug Resistance in <I>EGFR</I>-Mutant Non-Small Cell Lung Cancer

Heterogeneity of Drug Resistance in EGFR-Mutant Non-Small Cell Lung Cancer

By

The heterogeneity of resistance may make it difficult for drug developers to create combination therapies that prevent eventual resistance to osimertinib.

Lurbinectedin Receives FDA Orphan Drug Status for Recurrent Small-Cell Lung Cancer

Lurbinectedin Receives FDA Orphan Drug Status for Recurrent Small-Cell Lung Cancer

By

Small cell lung cancer, a highly aggressive disease, is diagnosed in 34,000 patients and accounts for nearly 18% of all lung cancer cases in the United States every year.

Osimertinib May Be Effective for CNS Metastases in Non-Small Cell Lung Cancer

Osimertinib May Be Effective for CNS Metastases in Non-Small Cell Lung Cancer

By

Previous studies have demonstrated that osimertinib may have the potential to improve outcomes among patients with central nervous system metastases.

Routine, Targeted Next-Generation Sequencing Is Feasible for Patients with Non-Small Cell Lung Cancer

Routine, Targeted Next-Generation Sequencing Is Feasible for Patients with Non-Small Cell Lung Cancer

By

Researchers retrospectively examined 2448 cases of NSCLC submitted to a single diagnostics lab over 3 years.

Fulvestrant Plus Erlotinib May Improve Progression-Free Survival in <I>EGFR</I> Wild-Type NSCLC

Fulvestrant Plus Erlotinib May Improve Progression-Free Survival in EGFR Wild-Type NSCLC

By

Recent findings identified interactions between the EGFR and estrogen receptor signaling pathways, which could potentially modify outcomes in non-small cell lung cancer.

Upfront Next-Generation Sequencing Is Faster, More Cost-Effective in Metastatic NSCLC

Upfront Next-Generation Sequencing Is Faster, More Cost-Effective in Metastatic NSCLC

By

The researchers argue that upfront next-generation sequencing should be the new standard of care.

Role of <i>BRAF</i> Mutations in Non-Small Cell Lung Cancer Still Emerging, Evolving

Role of BRAF Mutations in Non-Small Cell Lung Cancer Still Emerging, Evolving

By

"BRAF-mutated NSCLC represents an emerging targetable entity among the scenario of oncogene-driven NSCLC."

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in <i>EGFR</i>-Positive NSCLC

Gefitinib Plus Platinum-Doublet Chemotherapy May Improve Overall Survival in EGFR-Positive NSCLC

By

EGFR tyrosine kinase inhibitor monotherapy has improved progression-free survival (PFS) but not overall survival (OS) compared with chemotherapy in non-small cell lung cancer.

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

Bevacizumab Plus Erlotinib May Be a New Standard of Care in Non-Small Cell Lung Cancer

By

Recent studies have explored the potential of combination therapy with EGFR-TKIs and VEGF-inhibitors for patients with EGFR-positive non-small cell lung cancer.

Phase II Data of Tepotinib for Non-Small Cell Lung Cancer

Phase II Data of Tepotinib for Non-Small Cell Lung Cancer

Enriqueta Felip, MD, PhD, discusses her findings at the ASCO 2018 meeting in Chicago.

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

Prophylactic Cranial Irradiation Reduces the Incidence of Brain Metastases in NSCLC

By

Some figures show that incidence of brain metastasis is approximately 30% 2 years after being diagnosed with non-small cell lung cancer.

Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC

Pembrolizumab and Chemotherapy Combination Significantly Improves PFS in NSCLC

By

The phase 3 study found the combination effective, regardless of tumor proportion score.

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?

Immunotherapy for Lung Cancer: Are Combination Regimens a Path Forward?

By

PD-1/PD-L1 ICI can offer remarkable benefits as first- and second-line treatments for NSCLC, but 80% of patients do not respond to immunotherapy, and many of those who do respond eventually see their cancers acquire drug resistance.

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

Timely Reporting of Palliative Care Needs Leads to More Appropriate End-of-Life Care in NSCLC

By

Researchers accessed the French National Hospital registry and obtained the records of 64,950 patients who died of metastatic NSCLC between 2010 and 2013.

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

Osimertinib Improves Quality-of-Life and Global Health Status in Non-Small Cell Lung Cancer

By

Non-small cell lung cancer largely remains incurable and is associated with high symptom burden and reduced quality of life.

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

CTCs May Not Have Genetic Changes Found in Primary Lung Tumors

By

At surgery, blood samples were taken from 163 patients; whole genome sequencing and whole exome signaling were performed on detected CTCs.

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

Crizotinib Leads to Durable Benefit in ROS1-Positive Non-Small Cell Lung Cancer

By

Previous studies have demonstrated that crizotinib — a tyrosine kinase inhibitor (TKI) of ALK, MET, and ROS1 kinases — has markedly increased antitumor activity among patients with ROS1-positive NSCLC.

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

Long-Term Gefitinib Can Be Effective in Patients With NSCLC

By

Few long-term data of the drug's safety and efficacy in patients with NSCLC were previously available.

NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status

NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status

By

Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.

Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC

Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC

By

The safety profile of each agent was consistent with those previously reported.

NSCLC: Stratifying Patients With Complex <i>EGFR</i> Mutations

NSCLC: Stratifying Patients With Complex EGFR Mutations

By

Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.

Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches

Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches

By

Efforts are underway to develop predictive molecular biomarkers that can improve patient selection for ICIs.

NSCLC: Fruquintinib May Prolong PFS in Third-, Fourth-Line Setting

NSCLC: Fruquintinib May Prolong PFS in Third-, Fourth-Line Setting

By

Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.

FDA Approves Durvalumab for Prevention of NSCLC Progression

FDA Approves Durvalumab for Prevention of NSCLC Progression

By

The FDA based its approval on positive findings from the phase 3 PACIFIC study.

Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

Lung, Urothelial Cancers: Phase 1b/2 Trial of Avelumab With Chemotherapy

By

Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.

Elderly Patients With NSCLC Are Often Undertreated

Elderly Patients With NSCLC Are Often Undertreated

By

Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.

Proton Therapy May Not Reduce Radiation Exposure in Non-small Cell Lung Cancer

Proton Therapy May Not Reduce Radiation Exposure in Non-small Cell Lung Cancer

By

PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

Phase 2 Trial of SBRT and Gene Therapy Prior to Nivolumab for NSCLC

By

Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.

Priming Lung Cancer to Respond to Immunotherapy: Findings and Current Research

Priming Lung Cancer to Respond to Immunotherapy: Findings and Current Research

By

One trial is evaluating whether an HDAC inhibitor, mocetinostat, in combination with a demethylating drug, guadecitabine, can boost responses to pembrolizumab in patients with advanced NSCLC.

Chemotherapy Followed by Radiotherapy Improves Survival in Negative-margin NSCLC

Chemotherapy Followed by Radiotherapy Improves Survival in Negative-margin NSCLC

By

Data from previous studies suggest that adjuvant chemotherapy and PORT may improve patient outcomes, but the optimal sequence of administration was previously unestablished.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs